–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE...
Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study PUL 2.0 year-over-year decline attenuated to approximately 1 point Findings to be presented...
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced...
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself...
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb...
Barchart Research What to Expect from CAPR Earnings CAPR Generated May 11, 2026 Current Price $31.90 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 8.56% Capricor Therapeutics Faces Pivotal...
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics  (NASDAQ: CAPR), a biotechnology company developing transformative...
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced...